leuprolide

(redirected from Viadur)
Also found in: Medical.

leu·pro·lide

 (lo͞o′prō-līd′)
n.
A drug that is a synthetic polypeptide analog of naturally occurring gonadotropin-releasing hormone, C29H84N16O12, used in its acetate form to treat advanced prostate cancer.

Mentioned in ?
References in periodicals archive ?
These include Abbott's Lupron, AstraZeneca's Zoladex, Sanofi's Eligard, Watson Pharmaceuticals' Trelstar, Endo Pharmaceuticals' Vantas, Alza's Viadur, Pfizer's Synarel and several generic versions.
The FDA has not made any conclusions about whether diabetes or these cardiovascular diseases are caused by treatment with these drugs, which are available in generic formulations and as brand-name products (Lupron, Eligard, Synarel, Trelstar, Vantas, Viadur, and Zoladex).
and leuprolide acetate, sold as Lupron, Eligard, Viadur and as generics.
Some of the products developed through these off-balance sheet arrangements include Ditropan XL for over active bladder, Concerta for hyperactivity, and the cancer treatments known as Viadur and Doxil.
Martell has served concurrently as Assistant Clinical Professor of Oncology at Yale University School of Medicine and Staff Physician at the Veterans Affairs hospital, and he also worked at Bayer Pharmaceutical Division, where he oversaw the Phase I and Phase II studies for BAY 43-9006 (Sorafenib, a RAF Kinase/VEGF/PDGF inhibitor) and the post-marketing clinical development of Viadur.
Medications in the GnRH class are marketed under the brand names Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, and Zoladex.
The market is currently driven by the use of hormonal therapies: AstraZeneca's Zoladex (goserelin) and Casodex (bicalutamide), TAP Pharmaceutical Products' (Abbott/Takeda) Lupron (leuprolide subcutaneous injection or intramuscular depot), Sanofi-Aventis/Astellas Pharma's Eligard (leuprolide subcutaneous depot) and Bayer Schering Pharma's Viadur (leuprolide subcutaneous implant).
Based on diminished market demand and growing manufacturing costs, Bayer HealthCare Pharmaceuticals has concluded that Viadur has limited long-term market viability.
Bayer's Viadur (leuprolide), for the treatment of prostate cancer, will also be aligned with the Oncology unit.
Indevus is firmly committed to providing continuity of care for current Viadur patients," stated Kurt W.
Martell worked at Bayer Pharmaceutical Division; his last position was as Deputy Director Medical Science Unit, where he oversaw the Phase I and Phase II studies for BAY 43-9006 (Sorafenib, a RAF Kinase/VEGF/PDGF inhibitor) and the post-marketing clinical development of Viadur.
Avodart, Zoladex, Proscar, Casodex, Taxotere, Satraplatin, Plenaxis, EULEXIN, Trelstar Depot, Trelstar LA, Viadur, Gleevec, Avastin, Herceptin, Atrasentan, Acapodene, Actimid, OSI-461, Revimid, Eladem, GTI-2501, ILX-651, calcitrol, Genasense, Provenge , GVAX, SGN-15, Thalomid, Velcade, Lupron Depot, Histrelin, Eligard, ILX651, Vitaxin, J591, CG7870, BBR-3576, PCK3145, Leuvectin, Leuprolide, ProMaxx-100, Osaterone, Prinomastat, BLP25, Metaret, Chimax, Drogenil, Flutamide, EULEXIN, Onconase, IM862, MDX-010, Erbitux, Eladem, GTI-2040, Apomine, Eflornithine, Doxil, GTI-2501, Thalidomide, TG4010, KRX-0401, Yondelis, TRICOM Vaccine, Zarnestra